L
Overview
LFB develops and manufactures medicines from plasma and biotechnological products. It collects plasma, fractionates it to produce plasma-derived medicines, and develops recombinant proteins to treat rare diseases. Its distinction comes from its origins as a state-led public health mission that became a publicly owned company with the French State as sole shareholder, plus vertical integration (including EUROPLASMA) and sustained capital investments to secure its supply chain. Its goal is to ensure a reliable supply of essential medicines for public health while growing as a global biopharmaceutical company.
Work here?Claim your company
Simplify's take
What believers are saying
- Arras released first batches in November 2025, proving the new capacity is real.
- LFB collected 922,605 liters in France and 661,387 liters internationally during 2025.
- The company targets 3,336kL fractionation capacity by 2030, backed by €750 million.
What critics are saying
- Plasma supply remains the choke point; ANSM, EFS, and donor flows control output.
- Arras still concentrates execution risk; any contamination or validation failure halts growth.
- If France cannot secure enough plasma, LFB's public-mission model stalls despite Arras.
What makes LFB unique
- LFB remains France’s state-owned plasma champion, anchoring national medicine supply.
- Arras centralizes fractionation, purification, and fill-finish in one automated 2025 plant.
- Europlasma and American Plasma secure donor supply across Europe and the United States.
Help us improve and share your feedback! Did you find this helpful?